XBiotech Inc. (XBIT) annual income statement — 14-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 |
|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 4.01M | 18.39M | 44M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | -100% | -78.2% | -58.19% | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 332K | 1.69M | 0 | 0 | 651K | 5.82M | 34.55M | 2.36M | 2.43M | 1.48M | 698K | 699K | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | 16.23% | 31.64% | 78.52% | - | - | - | - | - | - | - | - |
| Gross Profit | -332K | -1.69M | 0 | 0 | 3.36M | 12.57M | 9.45M | -2.36M | -2.43M | -1.48M | -698K | -699K | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | 83.77% | 68.36% | 21.48% | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | -100% | -73.29% | 33.07% | 500.21% | 2.96% | -63.95% | -112.61% | 0.14% | - | - | - | - |
| Operating Expenses | 48.08M | 54M | 42.47M | 37.51M | 37.85M | 37.66M | 27.73M | 28.87M | 20.99M | 34.06M | 52.76M | 37.51M | 21.78M | 9.93M | 15.16M |
| OpEx % of Revenue | - | - | - | - | 943.87% | 204.72% | 63.02% | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 7.43M | 8.29M | 4.71M | 4.66M | 6.3M | 9.39M | 18.2M | 4.78M | 5.27M | 7.63M | 10.28M | 6.2M | 7.45M | 1.99M | 1.83M |
| SG&A % of Revenue | - | - | - | - | 157.23% | 51.04% | 41.36% | - | - | - | - | - | - | - | - |
| Research & Development | 40.98M | 47.39M | 37.76M | 32.85M | 31.54M | 28.27M | 9.53M | 24.09M | 15.72M | 26.42M | 42.49M | 31.31M | 14.33M | 7.93M | 13.33M |
| R&D % of Revenue | - | - | - | - | 786.63% | 153.68% | 21.65% | - | - | - | - | - | - | - | - |
| Other Operating Expenses | -332K | -1.69M | 0 | 0 | 0 | 0 | 0 | 0 | 4K | 0 | 0 | 21K | 0 | 0 | 0 |
| Operating Income | -48.41M | -55.69M | -42.47M | -37.51M | -34.49M | -25.08M | -18.28M | -31.23M | -20.99M | -34.06M | -52.76M | -37.51M | -21.78M | -9.93M | -15.16M |
| Operating Margin % | - | - | - | - | -860.1% | -136.36% | -41.54% | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -31.11% | -13.23% | -8.76% | -37.51% | -37.24% | 41.48% | -48.77% | 38.36% | 35.45% | -40.66% | -72.24% | -119.43% | 34.54% | - |
| EBITDA | -46.84M | -54M | -40.73M | -35.77M | -31.88M | -22.43M | -16.04M | -28.87M | -18.56M | -32.58M | -52.06M | -36.81M | -21.11M | -9.14M | -14.22M |
| EBITDA Margin % | - | - | - | - | -794.91% | -121.96% | -36.45% | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -7.88% | -32.59% | -13.87% | -12.2% | -42.09% | -39.88% | 44.45% | -55.55% | 43.02% | 37.43% | -41.44% | -74.34% | -130.98% | 35.7% | - |
| D&A (Non-Cash Add-back) | 1.58M | 1.69M | 1.75M | 1.74M | 2.61M | 2.65M | 2.24M | 2.36M | 2.43M | 1.48M | 698K | 699K | 664K | 784K | 946K |
| EBIT | -40.72M | -55.69M | -37.76M | -24.31M | -34.49M | -25.08M | -18.28M | 718.45M | -21.14M | -34.06M | -52.76M | -37.51M | -21.78M | -9.93M | -15.16M |
| Net Interest Income | 5.09M | 5.59M | 9.01M | 10.42M | 3.82M | 467K | 2.46M | 564K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 5.09M | 5.68M | 9.81M | 10.42M | 3.82M | 467K | 2.46M | 564K | 400K | 354K | 49K | 0 | 1K | 0 | 3K |
| Interest Expense | 0 | 88K | 807K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 8.51M | 10.38M | 3.91M | 13.2M | 902K | -376K | 5.45M | 749.69M | -144K | 909K | 2K | 27K | 54K | -2K | 3K |
| Pretax Income | -39.91M | -45.3M | -38.56M | -24.31M | -33.59M | -25.46M | -12.83M | 718.45M | -21.14M | -33.15M | -52.76M | -37.48M | -21.72M | -9.93M | -15.16M |
| Pretax Margin % | - | - | - | - | -837.61% | -138.4% | -29.15% | - | - | - | - | - | - | - | - |
| Income Tax | 255K | 235K | -32K | 244K | -688K | -8.04M | -1.61M | 49.82M | -144K | 0 | -2K | -6K | -54K | 2K | 0 |
| Effective Tax Rate % | -0.64% | -0.52% | 0.08% | -1% | 2.05% | 31.6% | 12.52% | 6.93% | 0.68% | 0% | 0% | 0.02% | 0.25% | -0.02% | 0% |
| Net Income | -40.16M | -45.54M | -38.53M | -24.56M | -32.9M | -17.41M | -11.22M | 668.63M | -21.14M | -33.15M | -52.76M | -37.48M | -21.72M | -9.93M | -15.16M |
| Net Margin % | - | - | - | - | -820.45% | -94.67% | -25.5% | - | - | - | - | - | - | - | - |
| Net Income Growth % | -1.9% | -18.19% | -56.9% | 25.36% | -88.93% | -55.19% | -101.68% | 3263.16% | 36.24% | 37.17% | -40.76% | -72.54% | -118.84% | 34.52% | - |
| Net Income (Continuing) | -40.16M | -45.54M | -38.53M | -24.56M | -32.9M | -17.41M | -11.22M | 668.63M | -21.14M | -33.15M | -52.76M | -37.48M | -21.72M | -9.93M | -15.16M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.32 | -1.49 | -1.26 | -0.81 | -1.08 | -0.58 | -0.36 | 14.44 | -0.59 | -0.95 | -1.63 | -1.22 | -0.68 | -0.31 | -0.48 |
| EPS Growth % | -2.14% | -18.25% | -55.56% | 25% | -86.21% | -61.11% | -102.49% | 2547.46% | 37.89% | 41.72% | -33.61% | -79.41% | -119.35% | 35.42% | - |
| EPS (Basic) | - | -1.49 | -1.26 | -0.81 | -1.08 | -0.58 | -0.36 | 17.17 | -0.59 | -0.95 | -1.63 | -1.22 | -0.68 | -0.31 | -0.48 |
| Diluted Shares Outstanding | 30.49M | 30.49M | 30.46M | 30.44M | 30.44M | 30.04M | 30.82M | 46.32M | 35.8M | 34.88M | 32.4M | 30.8M | 31.72M | 31.72M | 31.72M |
| Basic Shares Outstanding | 30.49M | 30.49M | 30.46M | 30.32M | 30.44M | 30.04M | 30.82M | 38.95M | 35.8M | 34.88M | 32.4M | 30.8M | 31.72M | 31.72M | 31.72M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying XBIT stock.
For fiscal year 2025, XBiotech Inc. (XBIT) reported total revenue of $0.0M.
XBiotech Inc. (XBIT) reported a net loss of $45.5M for the fiscal year ending 2025.